356057-34-6 | Darapladib

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$14.00	$10.00
5mg	98%	in stock	$35.00	$25.00
10mg	98%	in stock	$53.00	$37.00
25mg	98%	in stock	$103.00	$73.00
50mg	98%	in stock	$138.00	$97.00
250mg	95%	in stock	$387.00	$271.00
1g	95%	in stock	$1,132.00	$793.00

Description

• Catalog Number: AB72483
• Chemical Name: Darapladib
• CAS Number: 356057-34-6
• Molecular Formula: C36H38F4N4O2S
• Molecular Weight: 666.7711
• MDL Number: MFCD18251452
• SMILES: CCN(CCN(C(=O)Cn1c(SCc2ccc(cc2)F)nc(=O)c2c1CCC2)Cc1ccc(cc1)c1ccc(cc1)C(F)(F)F)CC

Computed Properties

• Complexity: 1120
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 47
• Hydrogen Bond Acceptor Count: 8
• Rotatable Bond Count: 13
• XLogP3: 7

Literature

• Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease.

  Current pharmaceutical design 20180101

• The associations of stroke, transient ischemic attack, and/or stroke-related recurrent vascular events with Lipoprotein-associated phospholipase A2: A systematic review and meta-analysis.

  Medicine 20171201

• Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA(2)).

  Journal of medicinal chemistry 20161208

• Darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in diabetic macular edema: a 3-month placebo-controlled study.

  Ophthalmology 20150501

• Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.

  JAMA 20140910

• Darapladib for preventing ischemic events in stable coronary heart disease.

  The New England journal of medicine 20140501

• Darapladib effect on circulating high sensitive troponin in patients with acute coronary syndromes.

  Atherosclerosis 20121101

• Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

  Journal of lipid research 20120901

• Relationship between cardiovascular risk factors and biomarkers with necrotic core and atheroma size: a serial intravascular ultrasound radiofrequency data analysis.

  The international journal of cardiovascular imaging 20120401

• Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.

  Lancet (London, England) 20120331

• Utility of Lp-PLA2 in lipid-lowering therapy.

  American journal of therapeutics 20120301

• Impact of analyzing fewer image frames per segment during offline volumetric radiofrequency-based intravascular ultrasound measurements of target lesions prior to percutaneous coronary interventions.

  The international journal of cardiovascular imaging 20120301

• Lysophosphatidylcholine: A Novel Modulator of Trypanosoma cruzi Transmission.

  Journal of parasitology research 20120101

• Circulating and PBMC Lp-PLA2 associate differently with oxidative stress and subclinical inflammation in nonobese women (menopausal status).

  PloS one 20120101

• Spatial orientation of cross-sectional images of coronary arteries: point of view in intracoronary imaging.

  Cardiovascular ultrasound 20120101

• Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins.

  Oncotarget 20111201

• Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).

  Current pharmaceutical design 20111101

• The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice.

  Acta pharmacologica Sinica 20111001

• Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.

  American heart journal 20111001

• Lipoprotein-associated phospholipase A2: how effective as a risk marker of cardiovascular disease and as a therapeutic target?

  Inflammation & allergy drug targets 20110801

• Peripheral artery disease, biomarkers, and darapladib.

  American heart journal 20110501

• The role of lipoprotein-associated phospholipase a₂ as a marker and potential therapeutic target in atherosclerosis.

  Current atherosclerosis reports 20110401

• IVUS-based imaging modalities for tissue characterization: similarities and differences.

  The international journal of cardiovascular imaging 20110201

• Ultrasound and light: friend or foe? On the role of intravascular ultrasound in the era of optical coherence tomography.

  The international journal of cardiovascular imaging 20110201

• Assessment of coronary atherosclerosis by IVUS and IVUS-based imaging modalities: progression and regression studies, tissue composition and beyond.

  The international journal of cardiovascular imaging 20110201

• [Novel therapy for atherosclerosis and inflammatory vascular disease].

  Nihon rinsho. Japanese journal of clinical medicine 20110101

• Study design and rationale of 'Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)' study: a double-blind randomised controlled multicenter clinical trial.

  Trials 20110101

• Focus on the research utility of intravascular ultrasound - comparison with other invasive modalities.

  Cardiovascular ultrasound 20110101

• Animal models of cardiovascular diseases.

  Journal of biomedicine & biotechnology 20110101

• Carriage of the V279F null allele within the gene encoding Lp-PLA₂ is protective from coronary artery disease in South Korean males.

  PloS one 20110101

• The vulnerable plaque: the real villain in acute coronary syndromes.

  The open cardiovascular medicine journal 20110101

• Racial variation in lipoprotein-associated phospholipase A₂ in older adults.

  BMC cardiovascular disorders 20110101

• Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice.

  PloS one 20110101

• Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a review.

  Lipids in health and disease 20110101

• Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes.

  Current opinion in lipidology 20101201

• Phospholipase A2s: developing drug targets for atherosclerosis.

  Atherosclerosis 20101001

• Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.

  American heart journal 20101001

• Darapladib: an emerging therapy for atherosclerosis.

  Therapeutic advances in cardiovascular disease 20100801

• Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes.

  Current opinion in cardiology 20100701

• Trial watch: a boost for GSK's first-in-class heart drug?

  Nature reviews. Drug discovery 20100701

• Extracellular phospholipases in atherosclerosis.

  Biochimie 20100601

• Impact of analyzing less image frames per segment for radiofrequency-based volumetric intravascular ultrasound measurements in mild-to-moderate coronary atherosclerosis.

  The international journal of cardiovascular imaging 20100601

• Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes.

  Diabetes 20100501

• Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.

  Lancet (London, England) 20100501

• A new method to measure necrotic core and calcium content in coronary plaques using intravascular ultrasound radiofrequency-based analysis.

  The international journal of cardiovascular imaging 20100401

• Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker.

  Expert review of cardiovascular therapy 20100301

• Lipoprotein-associated phospholipase A2: a new therapeutic target.

  The Canadian journal of cardiology 20100301

• Darapladib.

  Expert opinion on investigational drugs 20100101

• Lp-PLA2: A new target for statin therapy.

  Current atherosclerosis reports 20100101

• Association of carotid plaque Lp-PLA(2) with macrophages and Chlamydia pneumoniae infection among patients at risk for stroke.

  PloS one 20100101

• Impact of medical therapy on atheroma volume measured by different cardiovascular imaging modalities.

  Cardiology research and practice 20100101

• Lipoprotein-associated phospholipase A(2) and atherosclerosis.

  Current opinion in lipidology 20091001

• Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic.

  Expert opinion on investigational drugs 20091001

• Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.

  IDrugs : the investigational drugs journal 20091001

• Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target?

  Current atherosclerosis reports 20090901

• Phospholipase A2 inhibitors.

  Current opinion in lipidology 20090801

• Update on patented cholesterol absorption inhibitors.

  Expert opinion on therapeutic patents 20090801

• Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target.

  Current opinion in cardiology 20090701

• Phospholipase A2 inhibitors in atherosclerosis: the race is on.

  Lancet (London, England) 20090221

• Low and high density lipoprotein--cholesterol and coronary atherothrombosis.

  Medicinski pregled 20090101

• Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development.

  Nature medicine 20081001

• Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.

  Circulation 20080909

• Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier?

  Circulation 20080909

• The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.

  Journal of the American College of Cardiology 20080429

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080401

• Gateways to clinical trials. July-August 2008.

  Methods and findings in experimental and clinical pharmacology 20080101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060901

• The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.

  Bioorganic & medicinal chemistry letters 20030324

• Anti-inflammatory properties of a platelet-activating factor acetylhydrolase.

  Nature 19950406